<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02073682</url>
  </required_header>
  <id_info>
    <org_study_id>DU176b-D-U311</org_study_id>
    <secondary_id>2014-004708-30</secondary_id>
    <nct_id>NCT02073682</nct_id>
  </id_info>
  <brief_title>Cancer Venous Thromboembolism (VTE)</brief_title>
  <official_title>A Phase 3b, Prospective, Randomized, Open-label, Blind Evaluator (PROBE) Study Evaluating the Efficacy and Safety of (LMW) Heparin/Edoxaban Versus Dalteparin in Venous Thromboembolism Associated With Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to demonstrate the non-inferiority of edoxaban (preceded by a short
      course of LMWH) compared with dalteparin for the prevention of the combined outcome of
      recurrent venous thromboembolism (VTE) or major bleeding in subjects with VTE associated with
      cancer during a 12-month study period. If non-inferiority is established, LMWH/edoxaban will
      be compared with dalteparin for superiority.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 16, 2015</start_date>
  <completion_date type="Actual">September 15, 2017</completion_date>
  <primary_completion_date type="Actual">September 15, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adjudicated Recurrent Venous Thromboembolism (VTE) or Major Bleeding Event</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adjudicated Major Bleeding Events While on Treatment</measure>
    <time_frame>12 months</time_frame>
    <description>The primary safety endpoint was major bleeding events during the On-Treatment Study Period (defined as on-study drug or up to 3 days after the last dose of study drug).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Recurrent Venous Thromboembolism (VTE) During the Overall Study Period</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Recurrent Deep Vein Thrombosis (DVT) During the Overall Study Period</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Recurrent Non-Fatal Pulmonary Embolism (PE) During the Overall Study Period</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With VTE-Related Death</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Recurrent VTE, Major Bleed or All-Cause Death</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1046</enrollment>
  <condition>Venous Thromboembolism (VTE)</condition>
  <condition>Deep Vein Thrombosis (DVT)</condition>
  <condition>Pulmonary Embolism (PE)</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Edoxaban group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After 5 days of low molecular weight heparin (LMWH), patients receive edoxaban treatment daily - tablet for oral use</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dalteparin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive Dalteparin treatment daily -solution for subcutaneous injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edoxaban</intervention_name>
    <description>After the 5 day treatment with LMWH, patients receive edoxaban 60 mg once daily (QD) as 2 × 30 mg tablets (or 1 x 30 mg tablet QD for patients requiring dose adjustment) for the remainder of the treatment period.</description>
    <arm_group_label>Edoxaban group</arm_group_label>
    <other_name>DU-176b</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dalteparin</intervention_name>
    <description>Dalteparin was administered via subcutaneous injection at a dose of 200 IU/kg (maximum daily dose 18,000 IU) for 30 days, and at a dose of 150 IU/kg from Day 31 to the end of treatment.</description>
    <arm_group_label>Dalteparin group</arm_group_label>
    <other_name>Active comparator</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low molecular weight heparin</intervention_name>
    <description>Therapeutic doses of subcutaneous LMWH were administered for at least 5 days (to patients in the edoxaban group); this 5-day period may have included the pre-randomization LMWH (if applicable). The choice of parenteral LMWH was up to the treating physician.</description>
    <arm_group_label>Edoxaban group</arm_group_label>
    <other_name>LMWH</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects with age ≥ 18 years or the otherwise legal lower age according
             to the country of residence;

          -  Confirmed acute lower extremity proximal DVT or PE for which long term treatment with
             low molecular weight heparin (LMWH) is indicated;

          -  Cancer, other than basal-cell or squamous-cell carcinoma of the skin;

          -  Able to provide written informed consent.

        Exclusion Criteria:

          -  Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the
             current (index) episode of DVT and/or PE;

          -  Treatment with therapeutic doses of an anticoagulant other than that used for
             pretreatment of the current (index) VTE episode prior to randomization;

          -  Active bleeding or high risk for bleeding contraindicating treatment with LMWH or
             edoxaban;

          -  Any other contraindication listed in the local labeling of dalteparin, enoxaparin, or
             edoxaban;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Leader</last_name>
    <role>Study Director</role>
    <affiliation>Daiichi Sankyo, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jonesboro</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leuven</city>
        <state>Vlaams-Brabant</state>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint-Etienne cedex 2</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Debrecen</city>
        <state>Hajdu-Bihar Megye</state>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Varese</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>February 25, 2014</study_first_submitted>
  <study_first_submitted_qc>February 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2014</study_first_posted>
  <results_first_submitted>September 26, 2018</results_first_submitted>
  <results_first_submitted_qc>September 26, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 24, 2018</results_first_posted>
  <last_update_submitted>February 8, 2019</last_update_submitted>
  <last_update_submitted_qc>February 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Active Cancer with Metastasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Tinzaparin</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
    <mesh_term>Edoxaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/daiichi-sankyo/</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 20, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/82/NCT02073682/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>1050 participants were randomized from 114 sites in Western Europe (31), Central Europe (11), South Europe (36), Australia/New Zealand (13) and North America (23)</recruitment_details>
      <pre_assignment_details>Of 1050 participants randomized, 1046 took study drug and were included in the modified Intent to Treat (mITT) and Safety Analysis Sets</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Edoxaban Group</title>
          <description>After 5 days of low molecular weight heparin (LMWH), participants received edoxaban treatment daily</description>
        </group>
        <group group_id="P2">
          <title>Dalteparin Group</title>
          <description>Participants received dalteparin daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="522"/>
                <participants group_id="P2" count="524"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="200"/>
                <participants group_id="P2" count="154"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="322"/>
                <participants group_id="P2" count="370"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Low Creatinine Clearance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
                <participants group_id="P2" count="100"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Cancer Cured</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>ID: Patient Noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>ID: Palliative Treatment Only</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Prohibited Concomitant Medication Use</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Platelet Count &lt;50,000/mL</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Surgery/Medical Procedure</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Start of New Chemotherapy Regimen</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Cancer Progression</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
                <participants group_id="P2" count="62"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No reason provided</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>PD: Inconvenience of Dosing</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="78"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>ID: Benefit/Risk Judgment</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Edoxaban Group</title>
          <description>After 5 days of low molecular weight heparin (LMWH), participants received edoxaban treatment daily</description>
        </group>
        <group group_id="B2">
          <title>Dalteparin Group</title>
          <description>Participants received dalteparin daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="522"/>
            <count group_id="B2" value="524"/>
            <count group_id="B3" value="1046"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="522"/>
                    <count group_id="B2" value="524"/>
                    <count group_id="B3" value="1046"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66" lower_limit="22" upper_limit="91"/>
                    <measurement group_id="B2" value="65" lower_limit="21" upper_limit="89"/>
                    <measurement group_id="B3" value="65" lower_limit="21" upper_limit="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>18-64 Years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="522"/>
                    <count group_id="B2" value="524"/>
                    <count group_id="B3" value="1046"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="246"/>
                    <measurement group_id="B2" value="261"/>
                    <measurement group_id="B3" value="507"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>65-84 Years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="522"/>
                    <count group_id="B2" value="524"/>
                    <count group_id="B3" value="1046"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="267"/>
                    <measurement group_id="B2" value="254"/>
                    <measurement group_id="B3" value="521"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>85 years and over</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="522"/>
                    <count group_id="B2" value="524"/>
                    <count group_id="B3" value="1046"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="522"/>
                    <count group_id="B2" value="524"/>
                    <count group_id="B3" value="1046"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="245"/>
                    <measurement group_id="B2" value="261"/>
                    <measurement group_id="B3" value="506"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="277"/>
                    <measurement group_id="B2" value="263"/>
                    <measurement group_id="B3" value="540"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <population>The number analyzed in rows differs from overall because information was not provided by some participants: 13 in the edoxaban group and 18 in the dalteparin group.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="509"/>
                    <count group_id="B2" value="506"/>
                    <count group_id="B3" value="1015"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="453"/>
                    <measurement group_id="B2" value="427"/>
                    <measurement group_id="B3" value="880"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="509"/>
                    <count group_id="B2" value="506"/>
                    <count group_id="B3" value="1015"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="509"/>
                    <count group_id="B2" value="506"/>
                    <count group_id="B3" value="1015"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian/Pacific Islander</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="509"/>
                    <count group_id="B2" value="506"/>
                    <count group_id="B3" value="1015"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="509"/>
                    <count group_id="B2" value="506"/>
                    <count group_id="B3" value="1015"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Netherlands</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="522"/>
                    <count group_id="B2" value="524"/>
                    <count group_id="B3" value="1046"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="522"/>
                    <count group_id="B2" value="524"/>
                    <count group_id="B3" value="1046"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="522"/>
                    <count group_id="B2" value="524"/>
                    <count group_id="B3" value="1046"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="522"/>
                    <count group_id="B2" value="524"/>
                    <count group_id="B3" value="1046"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="522"/>
                    <count group_id="B2" value="524"/>
                    <count group_id="B3" value="1046"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="522"/>
                    <count group_id="B2" value="524"/>
                    <count group_id="B3" value="1046"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="522"/>
                    <count group_id="B2" value="524"/>
                    <count group_id="B3" value="1046"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="522"/>
                    <count group_id="B2" value="524"/>
                    <count group_id="B3" value="1046"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czechia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="522"/>
                    <count group_id="B2" value="524"/>
                    <count group_id="B3" value="1046"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="522"/>
                    <count group_id="B2" value="524"/>
                    <count group_id="B3" value="1046"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="522"/>
                    <count group_id="B2" value="524"/>
                    <count group_id="B3" value="1046"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New Zealand</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="522"/>
                    <count group_id="B2" value="524"/>
                    <count group_id="B3" value="1046"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="522"/>
                    <count group_id="B2" value="524"/>
                    <count group_id="B3" value="1046"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Type of Cancer</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Solid Tumor</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="522"/>
                    <count group_id="B2" value="524"/>
                    <count group_id="B3" value="1046"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="465"/>
                    <measurement group_id="B2" value="467"/>
                    <measurement group_id="B3" value="932"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haematological Malignancy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="522"/>
                    <count group_id="B2" value="524"/>
                    <count group_id="B3" value="1046"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Solid Tumor and Haematological Malignancy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="522"/>
                    <count group_id="B2" value="524"/>
                    <count group_id="B3" value="1046"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adjudicated Recurrent Venous Thromboembolism (VTE) or Major Bleeding Event</title>
        <time_frame>12 months</time_frame>
        <population>modified Intent to Treat (mITT), equating to the Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Edoxaban Group</title>
            <description>After 5 days of low molecular weight heparin (LMWH), participants received edoxaban treatment daily</description>
          </group>
          <group group_id="O2">
            <title>Dalteparin Group</title>
            <description>Participants received dalteparin daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adjudicated Recurrent Venous Thromboembolism (VTE) or Major Bleeding Event</title>
          <population>modified Intent to Treat (mITT), equating to the Safety Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="522"/>
                <count group_id="O2" value="524"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Edoxaban Group was considered non-inferior to the Dalteparin Group if the upper limit of the 2-sided 95% confidence interval (CI) for the Hazard Ratio ([LMW] Edoxaban Group to Dalteparin Group) was less than 1.5.</non_inferiority_desc>
            <p_value>0.0056</p_value>
            <method>Cox proportional hazard</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.696</ci_lower_limit>
            <ci_upper_limit>1.359</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The hazard ratio (HR), two-sided confidence interval (CI) and p-value are based on the Cox proportional hazard model including treatment and the two stratification factors as covariates: the dichotomized bleeding risk and the dichotomized dose-adjustment factor.</non_inferiority_desc>
            <p_value>0.8712</p_value>
            <method>Cox proportional hazard</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adjudicated Major Bleeding Events While on Treatment</title>
        <description>The primary safety endpoint was major bleeding events during the On-Treatment Study Period (defined as on-study drug or up to 3 days after the last dose of study drug).</description>
        <time_frame>12 months</time_frame>
        <population>Safety analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Edoxaban Group</title>
            <description>After 5 days of low molecular weight heparin (LMWH), participants received edoxaban treatment daily</description>
          </group>
          <group group_id="O2">
            <title>Dalteparin Group</title>
            <description>Participants received dalteparin daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adjudicated Major Bleeding Events While on Treatment</title>
          <description>The primary safety endpoint was major bleeding events during the On-Treatment Study Period (defined as on-study drug or up to 3 days after the last dose of study drug).</description>
          <population>Safety analysis set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="522"/>
                <count group_id="O2" value="524"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The HR, 2-sided CI and p-value are based on the Cox regression model with counting process approach for on-treatment including treatment and the 2 stratification factors as covariates: the dichotomized bleeding risk and the dichotomized dose-adjustment factor.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0254</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>2.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.089</ci_lower_limit>
            <ci_upper_limit>3.657</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Recurrent Venous Thromboembolism (VTE) During the Overall Study Period</title>
        <time_frame>12 months</time_frame>
        <population>mITT (Safety Analysis Set)</population>
        <group_list>
          <group group_id="O1">
            <title>Edoxaban Group</title>
            <description>After 5 days of low molecular weight heparin (LMWH), participants received edoxaban treatment daily</description>
          </group>
          <group group_id="O2">
            <title>Dalteparin Group</title>
            <description>Participants received dalteparin daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Recurrent Venous Thromboembolism (VTE) During the Overall Study Period</title>
          <population>mITT (Safety Analysis Set)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="522"/>
                <count group_id="O2" value="524"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The HR, 2-sided CI, and p-value are based on the Cox proportional hazard model including treatment and the 2 stratification factors as covariates: the dichotomized bleeding risk and the dichotomized dose-adjustment factor.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0931</p_value>
            <method>Cox proportional hazard</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.476</ci_lower_limit>
            <ci_upper_limit>1.059</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Recurrent Deep Vein Thrombosis (DVT) During the Overall Study Period</title>
        <time_frame>12 months</time_frame>
        <population>mITT (Safety Analysis Set)</population>
        <group_list>
          <group group_id="O1">
            <title>Edoxaban Group</title>
            <description>After 5 days of low molecular weight heparin (LMWH), participants received edoxaban treatment daily</description>
          </group>
          <group group_id="O2">
            <title>Dalteparin Group</title>
            <description>Participants received dalteparin daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Recurrent Deep Vein Thrombosis (DVT) During the Overall Study Period</title>
          <population>mITT (Safety Analysis Set)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="522"/>
                <count group_id="O2" value="524"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The HR, 2-sided CI, and p-value are based on the Cox proportional hazard model including treatment and the 2 stratification factors as covariates: the dichotomized bleeding risk and the dichotomized dose-adjustment factor.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0394</p_value>
            <method>Cox proportional hazard</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.318</ci_lower_limit>
            <ci_upper_limit>0.972</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Recurrent Non-Fatal Pulmonary Embolism (PE) During the Overall Study Period</title>
        <time_frame>12 months</time_frame>
        <population>mITT (Safety Analysis Set)</population>
        <group_list>
          <group group_id="O1">
            <title>Edoxaban Group</title>
            <description>After 5 days of low molecular weight heparin (LMWH), participants received edoxaban treatment daily</description>
          </group>
          <group group_id="O2">
            <title>Dalteparin Group</title>
            <description>Participants received dalteparin daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Recurrent Non-Fatal Pulmonary Embolism (PE) During the Overall Study Period</title>
          <population>mITT (Safety Analysis Set)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="522"/>
                <count group_id="O2" value="524"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The HR, 2-sided CI, and p-value are based on the Cox proportional hazard model including treatment and the 2 stratification factors as covariates: the dichotomized bleeding risk and the dichotomized dose-adjustment factor.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7324</p_value>
            <method>Cox proportional hazard</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.502</ci_lower_limit>
            <ci_upper_limit>1.624</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With VTE-Related Death</title>
        <time_frame>12 months</time_frame>
        <population>mITT (Safety Analysis Set)</population>
        <group_list>
          <group group_id="O1">
            <title>Edoxaban Group</title>
            <description>After 5 days of low molecular weight heparin (LMWH), participants received edoxaban treatment daily</description>
          </group>
          <group group_id="O2">
            <title>Dalteparin Group</title>
            <description>Participants received dalteparin daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With VTE-Related Death</title>
          <population>mITT (Safety Analysis Set)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="522"/>
                <count group_id="O2" value="524"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The HR, 2-sided CI, and p-value are based on the Cox proportional hazard model including treatment and the 2 stratification factors as covariates: the dichotomized bleeding risk and the dichotomized dose-adjustment factor.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4873</p_value>
            <method>Cox proportional hazard</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>1.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.444</ci_lower_limit>
            <ci_upper_limit>5.505</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Recurrent VTE, Major Bleed or All-Cause Death</title>
        <time_frame>12 months</time_frame>
        <population>mITT (Safety Analysis Set)</population>
        <group_list>
          <group group_id="O1">
            <title>Edoxaban Group</title>
            <description>After 5 days of low molecular weight heparin (LMWH), participants received edoxaban treatment daily</description>
          </group>
          <group group_id="O2">
            <title>Dalteparin Group</title>
            <description>Participants received dalteparin daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Recurrent VTE, Major Bleed or All-Cause Death</title>
          <population>mITT (Safety Analysis Set)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="522"/>
                <count group_id="O2" value="524"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="235"/>
                    <measurement group_id="O2" value="228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The HR, 2-sided CI, and p-value are based on the Cox proportional hazard model including treatment and the 2 stratification factors as covariates: the dichotomized bleeding risk and the dichotomized dose-adjustment factor.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4199</p_value>
            <method>Cox proportional hazard</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.898</ci_lower_limit>
            <ci_upper_limit>1.293</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Edoxaban Group</title>
          <description>After 5 days of low molecular weight heparin (LMWH), participants received edoxaban treatment daily</description>
        </group>
        <group group_id="E2">
          <title>Dalteparin Group</title>
          <description>Participants received dalteparin daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="206" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="192" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="276" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="251" subjects_at_risk="524"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="522"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Heparin-induced thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Immune thrombocytopenic purpura</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Cardiovascular disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Intracardiac mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Pulseless electrical activity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial septal defect</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal incarcerated hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Abdominal wall haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Colonic fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="522"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Ileal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Peritoneal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Catheter site haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="522"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="522"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Euthanasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute hepatic failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Bile duct stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Portal vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Campylobacter gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Infectious pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Meningococcal sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="522"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Post procedural sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Postoperative abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="522"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Subdiaphragmatic abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Post procedural haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Stoma site haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Urinary tract stoma complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Vascular procedure complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Wound haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Creatinine renal clearance decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="522"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma gastric</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma pancreas</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Brain cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Cervix cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Cholangiocarcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Colorectal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Colorectal cancer metastatic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Endometrial adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Endometrial cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Gallbladder cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Glioblastoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Huerthle cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Liposarcoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma metastatic</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="522"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="522"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="522"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of unknown primary site</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Malignant anorectal neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" events="69" subjects_affected="69" subjects_at_risk="522"/>
                <counts group_id="E2" events="67" subjects_affected="67" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="522"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Metastases to rectum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Metastatic carcinoma of the bladder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Neoplasm progression</sub_title>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="522"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Ovarian cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma metastatic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Prostate cancer metastatic</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Rectal adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Rectal cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Renal cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Sarcoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Small cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Tumour haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Vulvar cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Basal ganglia haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Central nervous system haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Cerebral haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="522"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Intracranial haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="522"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Leukoencephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Spinal cord haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Thrombotic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>VIIth nerve paralysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Unintended pregnancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="522"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Renal infarct</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Genital haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="522"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Laryngeal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="522"/>
                <counts group_id="E2" events="17" subjects_affected="16" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="522"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="524"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Stevens-Johnson syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Arterial haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="522"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Embolism arterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Femoral artery embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="524"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="524"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="524"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="44" subjects_affected="41" subjects_at_risk="522"/>
                <counts group_id="E2" events="42" subjects_affected="30" subjects_at_risk="524"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="40" subjects_affected="34" subjects_at_risk="522"/>
                <counts group_id="E2" events="45" subjects_affected="37" subjects_at_risk="524"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Daiichi Sankyo US Contact for Clinical Trial Results</name_or_title>
      <organization>Daiichi Sankyo, Inc.</organization>
      <phone>1-908-992-6400</phone>
      <email>CTRinfo@DSI.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

